In today's world, Fispemifene has gained unprecedented relevance. Whether in the field of politics, science, culture or technology, Fispemifene has become a topic of constant interest and debate. Knowing more about Fispemifene and its implications is crucial to understanding the current landscape and the trends that are setting the course for the future. In this article we will explore the various facets of Fispemifene, from its origin to its impact on today's society, to offer a complete and updated view of this phenomenon.
Clinical data | |
---|---|
Other names | HM-101 |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C26H27ClO3 |
Molar mass | 422.95 g·mol−1 |
3D model (JSmol) | |
| |
|
Fispemifene (INN, USAN) (developmental code name HM-101) is a nonsteroidal selective estrogen receptor modulator (SERM) of the triphenylethylene group that was developed for the treatment of male hypogonadism but was abandoned and never marketed.[1][2][3] It reached phase II clinical trials for this indication before development was terminated in March 2016.[1] The drug failed to achieve statistical significance on key effectiveness endpoints in clinical trials and was discontinued by its developer for strategic reasons.[1]